Full-Time

Clinical Laboratory Assistant

Confirmed live in the last 24 hours

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Junior

Company Does Not Provide H1B Sponsorship

San Antonio, TX, USA

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Icon referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree (preferred)
  • 1 year of related experience in a Clinical Laboratory
  • Basic working knowledge of computers and Microsoft Office
  • Excellent written and verbal communication skills
  • Ability to handle large workload demands and troubleshoot issues timely
  • Experience in clinical laboratory sample processing
  • Ability to keep accurate, legible records and handle information in line with GCP/GLP/GDP
Responsibilities
  • Monitoring samples/Troubleshooting discrepancies
  • Consolidating created samples/containers (i.e. slides, blocks, reports, etc.)
  • Searching and retrieving documents and samples
  • Performing data entry/Monitoring e-mails and various correspondences
  • Checking that slides/blocks are properly barcoded and labeled
  • Assisting the pathologists with the technical/clerical work
Desired Qualifications
  • Bachelor’s degree (preferred)

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, allowing them to offer tailored solutions to meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the quality of life for patients.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances clinical trial efficiency and participant satisfaction.
  • Appointment of Barry Balfe as COO expected to drive growth and enhance customer value.
  • Recognition as Europe's Climate Leader enhances brand reputation and attracts eco-conscious clients.

What critics are saying

  • Securities fraud lawsuit could damage ICON's reputation and affect future business opportunities.
  • Integration challenges with Mural Health partnership may lead to delays or increased costs.
  • Underutilization of biomarkers in trials could hinder competitive advantage in neurodegenerative research.

What makes Icon unique

  • ICON offers a full range of consulting, development, and commercialization services globally.
  • The company focuses on reducing time to market, cost, and increasing quality for clients.
  • ICON has extensive experience in a broad range of therapeutic areas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

PharmiWeb
Mar 4th, 2025
​​Mural Health And Icon Announce Partnership To Enhance Participant And Site Experience In Clinical Trials​

BERWYN, PENNSYLVANIA and DUBLIN, IRELAND, 4 March 2025 - Mural Health Technologies, Inc., a patient-first clinical trial technology company, and ICON plc (NASDAQ: ICLR), a global healthcare intelligence and clinical research organisation, today announce a partnership to utilise the participant management and payments platform, Mural Link. ICON will ​utilise​ Mural Link’s innovative functionality related to clinical trial participant payments, tax management, travel and concierge support, site-participant communication tools, and novel reporting and analytics capabilities. “From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation,” said Sam Whitaker, CEO of Mural Health. “This partnership represents a shared vision of removing barriers to trial participation​ and advancing participation financial neutrality​, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities.”

PharmiWeb
Jan 9th, 2025
Biomarker And Trial Optimisation Needed To Drive R&D Progress In Alzheimer’S And Related Disorders – Icon Survey

Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s RD’. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation